Formycon Faces Choppy Waters Amid US Biosimilar Pricing Storm
Ustekinumab Pricing Bites; Cimerli ‘Paused’; Pembrolizumab Phase III Terminated
Unleashing a trio of major announcements, Formycon has indicated a gloomy outlook for US Stelara biosimilar pricing; revealed plans to pause commercialization of its Sandoz-partnered US Cimerli rival to Lucentis amid discounting from rivals; and set out ambitious plans to win FDA approval for its proposed Keytruda biosimilar without any Phase III data.
